These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma. Anderson KC; Prince HM Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096 [No Abstract] [Full Text] [Related]
3. Lenalidomide in the treatment of multiple myeloma: a review. Armoiry X; Aulagner G; Facon T J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia. Gozzetti A; Musto P; Defina M; D'Auria F; Papini G; Statuto T; D'Arena G; Bocchia M Br J Haematol; 2012 May; 157(4):497-8. PubMed ID: 22296516 [No Abstract] [Full Text] [Related]
5. Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy. Pretz J; Medeiros BC Am J Hematol; 2009 Oct; 84(10):698-9. PubMed ID: 19691102 [No Abstract] [Full Text] [Related]
6. CC-5013 MM 0017: a multicenter, randomized, parallel-group, double-blind, placebo-controlled study of CC-5013 plus dexamethasone versus dexamethasone alone in previously treated subjects with multiple myeloma. Clin Adv Hematol Oncol; 2003 Mar; 1(3):189-90. PubMed ID: 16224405 [No Abstract] [Full Text] [Related]
7. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241 [TBL] [Abstract][Full Text] [Related]
8. [Plasma cell leukaemia]. Rodriguez C; Pont JC; Gouin-Thibault I; Andrieu AG; Molina T; Le Tourneau A; Le Garff-Tavernier M; Siguret V; Chaibi P Ann Biol Clin (Paris); 2005; 63(5):535-9. PubMed ID: 16230292 [TBL] [Abstract][Full Text] [Related]
13. Lenalidomide and its role in the management of multiple myeloma. Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796 [TBL] [Abstract][Full Text] [Related]
14. Kappa light chain myeloma with initial cutaneous involvement. Saka B; Erten N; Oztürk G; Yilmaz C; Dogan O; Buyukbabani N; Besisik SK Ann Hematol; 2006 Apr; 85(4):272-4. PubMed ID: 16425024 [No Abstract] [Full Text] [Related]
15. Primary plasma cell leukemia occuring in the young. Raj RS; Najeeb S; Aruna R; Pavithran K; Thomas M Indian J Cancer; 2003; 40(3):116-7. PubMed ID: 14716116 [TBL] [Abstract][Full Text] [Related]
16. Lenalidomide can induce graft versus leukemia effect in primary plasma cell leukemia: a case report. Olivieri A; Attolico I; Cimminiello M; Discepoli G; Cifarelli RA Leuk Res; 2009 Nov; 33(11):e191-3. PubMed ID: 19476997 [No Abstract] [Full Text] [Related]
18. Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone. Siniscalchi A; Tendas A; Morino L; Dentamaro T; De Bellis A; Perrotti A; de Fabritiis P; Musto P; Caravita T Support Care Cancer; 2012 Jul; 20(7):1585-7. PubMed ID: 22562584 [No Abstract] [Full Text] [Related]
19. Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy. Hazarika M; Rock E; Williams G; Dagher R; Sridhara R; Booth B; Farrell A; Justice R; Pazdur R Oncologist; 2008 Oct; 13(10):1120-7. PubMed ID: 18922829 [TBL] [Abstract][Full Text] [Related]
20. Treatment of multiple myeloma in the targeted therapy era. Saad AA; Sharma M; Higa GM Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]